Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Adaptive myelination from fish to man.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
RTL therapy for multiple sclerosis: a Phase I clinical study.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Motor skill learning requires active central myelination.
Novantrone (mitoxantrone HCl) Injection February 2009
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Alemtuzumab benefits hard-to-treat MS patients
Rituximab and multiple sclerosis.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Treatment of neurological injury with thymosin β4.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.

Pages